MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL

File: 970101_sep96_decls37_0009.txt
Page: 0009
Total Pages: 23

Subject: MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL                     

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003201

Folder Title: MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL                                                     

Document Number:       1001

Folder Seq  #:         31




                                        UNCLASSIFIED










           (1000 mg initially, followed by 750 mg bid) or doxycycline (200
           mg initially, followed by 100 mg q 12 hrs). Supportive therapy
           for shock, fluid volume deficit, and adequacy of airway may all
           be needed.



           @Wi-L",Ta

             Vaccine. A licensed, alum-precipitated, preparation of
           purified Bacillus anthracis protective antigen (PA) has been
           shown to be effective in preventing or significantly reducing
           the incidence of inhalation anthrax. Limited human data
           suggest that after completion of the first three doses of the
           recommended six-dose primary series protection against both
           cutaneous and inhalation anthrax is afforded. Studies in
           rhesus monkeys indicate that good protection is afforded after
           two doses (10-16 days apart) for up to 2 years. It is likely
           that two doses in humans is protective as well, but there is
           too little information to draw firm conclusions. As with all
           vaccines, the degree of protection depends upon the magnitude
           of the challenge dose; vaccine-induced protection is
           undoubtedly overwhelmed by extremely high spore challenge.

             In the present setting, three doses of the vaccine is
           recommended for prophylaxis against inhalation anthrax.
           Contraindications for use are sensitivity to vaccine components
           (formalin, alum, benzethonium chloride) and/or history of
           clinical anthrax. Reactagenicity is mild to moderate: up to
           6% of recipients will experience mild discomfort at the
           innoculation site for up to 72 hours (tenderness, erythema,
           edema, pruritus), while a smaller proportion (I%) will
           experience more severe local reactions (potentially limiting
           use of the extremity for 1-2 days); modest systemic reactions
laise, low-grade fever) are uncommon and severe
           systemic reactions (anaphylaxis, which precludes additional
           vaccination) are rare. The vaccine should be stored at
           refrigerator temperature (@ frozen).




             Choice of antibiotics for prophylaxis is guided by the same
           principles as that for treatment; i.e., it is relatively easy
           to produce a penicillin-resistant organism in the laboratory,



                                           6



                                         UNCLASSIFIED

Document 23 f:/Week-36/BX003201/MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL/medical defense against biological material:12249609313138
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL
Folder Seq # = 31
Subject = MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL
Document Seq # = 1001
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 24-DEC-1996